Covid-19 vaccine and MS

BioNTech, the German company involved in production of the first approved Covid-19 vaccine, is now applying its vaccine technology in multiple sclerosis research (MS).

This is the first application of mRNA vaccine technology for the treatment of an autoimmune disease, as previous research has focused on infectious diseases and cancer.

In collaboration with Johannes Gutenberg University of Mainz, the team has produced a vaccine which aims to reduce the abnormal immune responses seen in patients with MS.

The vaccine appears to improve symptoms of MS in mice with severe symptoms, while preventing progression of the disease in mice with early signs of MS, without overly suppressing the whole immune system.

Recent Posts

See All

Copyright © 2019 European Animal Research Association, All rights reserved.

European Animal Research Association 

London Office

Abbey House, 74-76 St John Street
London EC1M 4DZ
Tel: +44 (0)20 3675 1245

Brussels Office
52 Rue Marie de Bourgogne, 1st Floor
1000 Brussels,


  • Twitter
  • Facebook
  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon